Vital KSK Holdings, Inc. Provides Consolidated Earnings Guidance for the First Half and Full Year of Fiscal Year Ending March 31, 2025
May 13, 2024 at 01:00 am
Share
Vital KSK Holdings, Inc. provided consolidated earnings guidance for the first half and full year of fiscal year ending March 31, 2025. For the first half, the company expects net sales of JPY 296,000 million, operating profit of JPY 2,800 million, profit attributable to owners of parent of JPY 2,200 million and basic earnings per share of JPY 43.83.
For the full year, the company expects net sales of JPY 590,000 million, operating profit of JPY 5,500 million, profit attributable to owners of parent of JPY 6,000 million and basic earnings per share of JPY 119.53.
VITAL KSK HOLDINGS, INC. is a Japan-based holding company, principally engaged in the wholesale of drugs. The Pharmaceutical Wholesale segment is engaged in the wholesale of pharmaceuticals, diagnostics, medical equipment, materials to hospitals, medical practitioners, pharmacies and other medical institutions. The others business is engaged in dispensing pharmacy business, retail of pharmaceutical products, wholesale of agricultural chemicals and veterinary drugs, transportation business, nursing care business, consulting services for medical institutions, property insurance agency business, real estate brokerage business, as well as parking business.
VITAL KSK HOLDINGS, INC. 
